Molecular T-Cell Repertoire Analysis As Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Apr 3

PMID 32235561

Citations 35

Authors

Ilenia Aversa

Donatella Malanga

Giuseppe Fiume

Camillo Palmieri

Affiliations

Soon will be listed here.

Abstract

The T cells are key players of the response to checkpoint blockade immunotherapy (CBI) and monitoring the strength and specificity of antitumor T-cell reactivity remains a crucial but elusive component of precision immunotherapy. The entire assembly of T-cell receptor (TCR) sequences accounts for antigen specificity and strength of the T-cell immune response. The TCR repertoire hence represents a "footprint" of the conditions faced by T cells that dynamically evolves according to the challenges that arise for the immune system, such as tumor neo-antigenic load. Hence, TCR repertoire analysis is becoming increasingly important to comprehensively understand the nature of a successful antitumor T-cell response, and to improve the success and safety of current CBI.

Citing Articles

Elucidating the Role of the T Cell Receptor Repertoire in Myelodysplastic Neoplasms and Acute Myeloid Leukemia.

Barakos G, Georgoulis V, Koumpis E, Hatzimichael E Diseases. 2025; 13(1).

PMID: 39851483 PMC: 11765071. DOI: 10.3390/diseases13010019.

Analysis of Wilms' tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed.

Gielis S, Flumens D, van der Heijden S, Versteven M, De Reu H, Bartholomeus E Ann Hematol. 2024; 104(1):317-333.

PMID: 39259326 PMC: 11868354. DOI: 10.1007/s00277-024-05919-1.

Peripheral Blood TCRβ Repertoire, IL15, IL2 and Soluble Ligands for NKG2D Activating Receptor Predict Efficacy of Immune Checkpoint Inhibitors in Lung Cancer.

Sesma A, Pardo J, Isla D, M Galvez E, Gascon-Ruiz M, Martinez-Lostao L Cancers (Basel). 2024; 16(16).

PMID: 39199571 PMC: 11352724. DOI: 10.3390/cancers16162798.

Self-Assembled Nanocomposite DOX/TPOR@CB[7] for Enhanced Synergistic Photodynamic Therapy and Chemotherapy in Neuroblastoma.

Lu Z, Chen X, Wang C, Luo X, Wu X, Zhao X Pharmaceutics. 2024; 16(6).

PMID: 38931942 PMC: 11207937. DOI: 10.3390/pharmaceutics16060822.

Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy.

Qin Y, Huo M, Liu X, Cheng Li S Front Immunol. 2024; 15:1368749.

PMID: 38524135 PMC: 10957591. DOI: 10.3389/fimmu.2024.1368749.

References

Neller M, Burrows J, Rist M, Miles J, Burrows S . High frequency of herpesvirus-specific clonotypes in the human T cell repertoire can remain stable over decades with minimal turnover. J Virol. 2012; 87(1):697-700. PMC: 3536364. DOI: 10.1128/JVI.02180-12. View

Danilova L, Anagnostou V, Caushi J, Sidhom J, Guo H, Chan H . The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. Cancer Immunol Res. 2018; 6(8):888-899. PMC: 6072595. DOI: 10.1158/2326-6066.CIR-18-0129. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncol. 2019; 5(10):1411-1420. PMC: 6659167. DOI: 10.1001/jamaoncol.2019.2187. View

Qureshi O, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt E . Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011; 332(6029):600-3. PMC: 3198051. DOI: 10.1126/science.1202947. View

Kivioja T, Vaharautio A, Karlsson K, Bonke M, Enge M, Linnarsson S . Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods. 2011; 9(1):72-4. DOI: 10.1038/nmeth.1778. View

Bradley P, Thomas P . Using T Cell Receptor Repertoires to Understand the Principles of Adaptive Immune Recognition. Annu Rev Immunol. 2019; 37:547-570. DOI: 10.1146/annurev-immunol-042718-041757. View

Rosati E, Dowds C, Liaskou E, Henriksen E, Karlsen T, Franke A . Overview of methodologies for T-cell receptor repertoire analysis. BMC Biotechnol. 2017; 17(1):61. PMC: 5504616. DOI: 10.1186/s12896-017-0379-9. View

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

Ma K, He C, Wendel B, Williams C, Xiao J, Yang H . Immune Repertoire Sequencing Using Molecular Identifiers Enables Accurate Clonality Discovery and Clone Size Quantification. Front Immunol. 2018; 9:33. PMC: 5808239. DOI: 10.3389/fimmu.2018.00033. View

10.

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

11.

Greiff V, Miho E, Menzel U, Reddy S . Bioinformatic and Statistical Analysis of Adaptive Immune Repertoires. Trends Immunol. 2015; 36(11):738-749. DOI: 10.1016/j.it.2015.09.006. View

12.

Puri S, Shafique M . Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. Drugs Context. 2020; 9. PMC: 7048109. DOI: 10.7573/dic.2019-9-2. View

13.

Wang X, Zhang B, Yang Y, Zhu J, Cheng S, Mao Y . Characterization of Distinct T Cell Receptor Repertoires in Tumor and Distant Non-tumor Tissues from Lung Cancer Patients. Genomics Proteomics Bioinformatics. 2019; 17(3):287-296. PMC: 6818398. DOI: 10.1016/j.gpb.2018.10.005. View

14.

Yost K, Satpathy A, Wells D, Qi Y, Wang C, Kageyama R . Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019; 25(8):1251-1259. PMC: 6689255. DOI: 10.1038/s41591-019-0522-3. View

15.

Kalbasi A, Ribas A . Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2019; 20(1):25-39. PMC: 8499690. DOI: 10.1038/s41577-019-0218-4. View

16.

Schummer P, Schilling B, Gesierich A . Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?. Am J Clin Dermatol. 2020; 21(4):493-504. PMC: 7371660. DOI: 10.1007/s40257-020-00509-z. View

17.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

18.

Robins H, Campregher P, Srivastava S, Wacher A, Turtle C, Kahsai O . Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009; 114(19):4099-107. PMC: 2774550. DOI: 10.1182/blood-2009-04-217604. View

19.

Gunturi A, Mcdermott D . Nivolumab for the treatment of cancer. Expert Opin Investig Drugs. 2014; 24(2):253-60. DOI: 10.1517/13543784.2015.991819. View

20.

Weber J, DAngelo S, Minor D, Hodi F, Gutzmer R, Neyns B . Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16(4):375-84. DOI: 10.1016/S1470-2045(15)70076-8. View